Baseline characteristics of the patients, by dose of cytarabine
| Characteristic . | 200 mg/m2 cytarabine, dose levels I, II, IIIA, IVA; n = 107 . | 1000 mg/m2 cytarabine, dose levels IIIB, IVB, V; n = 55 . |
|---|---|---|
| Age at diagnosis, y | ||
| Median | 48 | 46 |
| Range | 20-65 | 19-62 |
| Sex, no. (%) | ||
| Male | 64 (60) | 31 (56) |
| Female | 43 (40) | 24 (44) |
| Spleen size, cm below midleft costal margin | ||
| Median | 3 | 1 |
| Range | 0-27 | 0-30 |
| Platelet count, ×109/L | ||
| Median | 412 | 357 |
| Range | 152-1908 | 92-1584 |
| Blasts in peripheral blood, % | ||
| Median | 1 | 1 |
| Range | 0-12 | 0-16 |
| Sokal risk group, no. (%) | ||
| Low, less than 0.8 | 30 (28) | 28 (51) |
| Intermediate, 0.8 to 1.2 | 40 (37) | 11 (20) |
| High, more than 1.2 | 31 (29) | 12 (22) |
| Unknown | 6 (6) | 4 (7) |
| Dose imatinib, no. (%) | ||
| 200 mg | 5 (5) | — |
| 400 mg | 29 (27) | 15 (27) |
| 600 mg | 21 (20) | 20 (36) |
| 800 mg | 52 (49) | 20 (36) |
| Characteristic . | 200 mg/m2 cytarabine, dose levels I, II, IIIA, IVA; n = 107 . | 1000 mg/m2 cytarabine, dose levels IIIB, IVB, V; n = 55 . |
|---|---|---|
| Age at diagnosis, y | ||
| Median | 48 | 46 |
| Range | 20-65 | 19-62 |
| Sex, no. (%) | ||
| Male | 64 (60) | 31 (56) |
| Female | 43 (40) | 24 (44) |
| Spleen size, cm below midleft costal margin | ||
| Median | 3 | 1 |
| Range | 0-27 | 0-30 |
| Platelet count, ×109/L | ||
| Median | 412 | 357 |
| Range | 152-1908 | 92-1584 |
| Blasts in peripheral blood, % | ||
| Median | 1 | 1 |
| Range | 0-12 | 0-16 |
| Sokal risk group, no. (%) | ||
| Low, less than 0.8 | 30 (28) | 28 (51) |
| Intermediate, 0.8 to 1.2 | 40 (37) | 11 (20) |
| High, more than 1.2 | 31 (29) | 12 (22) |
| Unknown | 6 (6) | 4 (7) |
| Dose imatinib, no. (%) | ||
| 200 mg | 5 (5) | — |
| 400 mg | 29 (27) | 15 (27) |
| 600 mg | 21 (20) | 20 (36) |
| 800 mg | 52 (49) | 20 (36) |
Percentages may not sum up to 100% due to rounding.
— indicates not applicable.